GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. NX-GBL-ON-OGM-210034. December 2021.
Brands: https://ash.gskoncologypipeline.com/Banner/Virtual_Booth_Banner.jpg